The Absence of a Relation between the Periconceptional Use of Vitamins and Neural-Tube Defects

James L. Mills, George Rhoads, Joe Leigh Simpson, George C. Cunningham, Mary R. Conley, Melinda R. Lassman, Margaret E. Walden, O. Richard Depp, Howard J. Hoffman

Research output: Contribution to journalArticle

192 Citations (Scopus)

Abstract

Whether taking multivitamins or folate around the time of conception can reduce a woman's risk of having a child with a neural-tube defect is controversial. To investigate this question, we examined the periconceptional use of vitamin supplements by women who had a conceptus with a neural-tube defect (n = 571), women who had had a stillbirth or a conceptus with another malformation (n = 546), and women who had had a normal conceptus (n = 573). Women with conceptuses with neural-tube defects were identified either prenatally or postnatally and were matched to control mothers for gestational age. To minimize recall bias, we interviewed nearly all the women within five months of the diagnosis of a birth defect or the birth of the infant (mean, 84 days); information on vitamin use was obtained by an interviewer who was unaware of the outcome of pregnancy. The rate of periconceptional multivitamin use among the mothers of infants with neural-tube defects (15.8 percent) was not significantly different from the rate among mothers in either the abnormal or the normal control group (14.1 percent and 15.9 percent, respectively). After adjustment for potential confounding factors, the odds ratio for having an infant with a neural-tube defect among women classified as having had full supplementation with multivitamins was 0.95 as compared with the mothers of the abnormal infants (95 percent confidence interval, 0.78 to 1.14) and 1.00 as compared with the mothers of normal infants (95 percent confidence interval, 0.83 to 1.20). There were no differences among the groups in the use of folate supplements. The adjusted odds ratio for having an infant with a neural-tube defect among those receiving the recommended daily allowance of folate was 0.97 as compared with the mothers of abnormal infants (95 percent confidence interval, 0.79 to 1.18) and 0.98 as compared with the mothers of normal infants (95 percent confidence interval, 0.80 to 1.20). We conclude that the periconceptional use of multivitamins or folate-containing supplements by American women does not decrease the risk of having an infant with a neural-tube defect. (N Engl J Med 1989; 321:430–5).

Original languageEnglish (US)
Pages (from-to)430-435
Number of pages6
JournalNew England Journal of Medicine
Volume321
Issue number7
DOIs
StatePublished - Aug 17 1989

Fingerprint

Neural Tube Defects
Vitamins
Mothers
Folic Acid
Confidence Intervals
Odds Ratio
Recommended Dietary Allowances
Stillbirth
Pregnancy Outcome
Gestational Age
Parturition
Interviews
Control Groups

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Mills, J. L., Rhoads, G., Simpson, J. L., Cunningham, G. C., Conley, M. R., Lassman, M. R., ... Hoffman, H. J. (1989). The Absence of a Relation between the Periconceptional Use of Vitamins and Neural-Tube Defects. New England Journal of Medicine, 321(7), 430-435. https://doi.org/10.1056/NEJM198908173210704
Mills, James L. ; Rhoads, George ; Simpson, Joe Leigh ; Cunningham, George C. ; Conley, Mary R. ; Lassman, Melinda R. ; Walden, Margaret E. ; Depp, O. Richard ; Hoffman, Howard J. / The Absence of a Relation between the Periconceptional Use of Vitamins and Neural-Tube Defects. In: New England Journal of Medicine. 1989 ; Vol. 321, No. 7. pp. 430-435.
@article{312a7e43be0d4b0895d8cdd992fcfd18,
title = "The Absence of a Relation between the Periconceptional Use of Vitamins and Neural-Tube Defects",
abstract = "Whether taking multivitamins or folate around the time of conception can reduce a woman's risk of having a child with a neural-tube defect is controversial. To investigate this question, we examined the periconceptional use of vitamin supplements by women who had a conceptus with a neural-tube defect (n = 571), women who had had a stillbirth or a conceptus with another malformation (n = 546), and women who had had a normal conceptus (n = 573). Women with conceptuses with neural-tube defects were identified either prenatally or postnatally and were matched to control mothers for gestational age. To minimize recall bias, we interviewed nearly all the women within five months of the diagnosis of a birth defect or the birth of the infant (mean, 84 days); information on vitamin use was obtained by an interviewer who was unaware of the outcome of pregnancy. The rate of periconceptional multivitamin use among the mothers of infants with neural-tube defects (15.8 percent) was not significantly different from the rate among mothers in either the abnormal or the normal control group (14.1 percent and 15.9 percent, respectively). After adjustment for potential confounding factors, the odds ratio for having an infant with a neural-tube defect among women classified as having had full supplementation with multivitamins was 0.95 as compared with the mothers of the abnormal infants (95 percent confidence interval, 0.78 to 1.14) and 1.00 as compared with the mothers of normal infants (95 percent confidence interval, 0.83 to 1.20). There were no differences among the groups in the use of folate supplements. The adjusted odds ratio for having an infant with a neural-tube defect among those receiving the recommended daily allowance of folate was 0.97 as compared with the mothers of abnormal infants (95 percent confidence interval, 0.79 to 1.18) and 0.98 as compared with the mothers of normal infants (95 percent confidence interval, 0.80 to 1.20). We conclude that the periconceptional use of multivitamins or folate-containing supplements by American women does not decrease the risk of having an infant with a neural-tube defect. (N Engl J Med 1989; 321:430–5).",
author = "Mills, {James L.} and George Rhoads and Simpson, {Joe Leigh} and Cunningham, {George C.} and Conley, {Mary R.} and Lassman, {Melinda R.} and Walden, {Margaret E.} and Depp, {O. Richard} and Hoffman, {Howard J.}",
year = "1989",
month = "8",
day = "17",
doi = "10.1056/NEJM198908173210704",
language = "English (US)",
volume = "321",
pages = "430--435",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "7",

}

Mills, JL, Rhoads, G, Simpson, JL, Cunningham, GC, Conley, MR, Lassman, MR, Walden, ME, Depp, OR & Hoffman, HJ 1989, 'The Absence of a Relation between the Periconceptional Use of Vitamins and Neural-Tube Defects', New England Journal of Medicine, vol. 321, no. 7, pp. 430-435. https://doi.org/10.1056/NEJM198908173210704

The Absence of a Relation between the Periconceptional Use of Vitamins and Neural-Tube Defects. / Mills, James L.; Rhoads, George; Simpson, Joe Leigh; Cunningham, George C.; Conley, Mary R.; Lassman, Melinda R.; Walden, Margaret E.; Depp, O. Richard; Hoffman, Howard J.

In: New England Journal of Medicine, Vol. 321, No. 7, 17.08.1989, p. 430-435.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The Absence of a Relation between the Periconceptional Use of Vitamins and Neural-Tube Defects

AU - Mills, James L.

AU - Rhoads, George

AU - Simpson, Joe Leigh

AU - Cunningham, George C.

AU - Conley, Mary R.

AU - Lassman, Melinda R.

AU - Walden, Margaret E.

AU - Depp, O. Richard

AU - Hoffman, Howard J.

PY - 1989/8/17

Y1 - 1989/8/17

N2 - Whether taking multivitamins or folate around the time of conception can reduce a woman's risk of having a child with a neural-tube defect is controversial. To investigate this question, we examined the periconceptional use of vitamin supplements by women who had a conceptus with a neural-tube defect (n = 571), women who had had a stillbirth or a conceptus with another malformation (n = 546), and women who had had a normal conceptus (n = 573). Women with conceptuses with neural-tube defects were identified either prenatally or postnatally and were matched to control mothers for gestational age. To minimize recall bias, we interviewed nearly all the women within five months of the diagnosis of a birth defect or the birth of the infant (mean, 84 days); information on vitamin use was obtained by an interviewer who was unaware of the outcome of pregnancy. The rate of periconceptional multivitamin use among the mothers of infants with neural-tube defects (15.8 percent) was not significantly different from the rate among mothers in either the abnormal or the normal control group (14.1 percent and 15.9 percent, respectively). After adjustment for potential confounding factors, the odds ratio for having an infant with a neural-tube defect among women classified as having had full supplementation with multivitamins was 0.95 as compared with the mothers of the abnormal infants (95 percent confidence interval, 0.78 to 1.14) and 1.00 as compared with the mothers of normal infants (95 percent confidence interval, 0.83 to 1.20). There were no differences among the groups in the use of folate supplements. The adjusted odds ratio for having an infant with a neural-tube defect among those receiving the recommended daily allowance of folate was 0.97 as compared with the mothers of abnormal infants (95 percent confidence interval, 0.79 to 1.18) and 0.98 as compared with the mothers of normal infants (95 percent confidence interval, 0.80 to 1.20). We conclude that the periconceptional use of multivitamins or folate-containing supplements by American women does not decrease the risk of having an infant with a neural-tube defect. (N Engl J Med 1989; 321:430–5).

AB - Whether taking multivitamins or folate around the time of conception can reduce a woman's risk of having a child with a neural-tube defect is controversial. To investigate this question, we examined the periconceptional use of vitamin supplements by women who had a conceptus with a neural-tube defect (n = 571), women who had had a stillbirth or a conceptus with another malformation (n = 546), and women who had had a normal conceptus (n = 573). Women with conceptuses with neural-tube defects were identified either prenatally or postnatally and were matched to control mothers for gestational age. To minimize recall bias, we interviewed nearly all the women within five months of the diagnosis of a birth defect or the birth of the infant (mean, 84 days); information on vitamin use was obtained by an interviewer who was unaware of the outcome of pregnancy. The rate of periconceptional multivitamin use among the mothers of infants with neural-tube defects (15.8 percent) was not significantly different from the rate among mothers in either the abnormal or the normal control group (14.1 percent and 15.9 percent, respectively). After adjustment for potential confounding factors, the odds ratio for having an infant with a neural-tube defect among women classified as having had full supplementation with multivitamins was 0.95 as compared with the mothers of the abnormal infants (95 percent confidence interval, 0.78 to 1.14) and 1.00 as compared with the mothers of normal infants (95 percent confidence interval, 0.83 to 1.20). There were no differences among the groups in the use of folate supplements. The adjusted odds ratio for having an infant with a neural-tube defect among those receiving the recommended daily allowance of folate was 0.97 as compared with the mothers of abnormal infants (95 percent confidence interval, 0.79 to 1.18) and 0.98 as compared with the mothers of normal infants (95 percent confidence interval, 0.80 to 1.20). We conclude that the periconceptional use of multivitamins or folate-containing supplements by American women does not decrease the risk of having an infant with a neural-tube defect. (N Engl J Med 1989; 321:430–5).

UR - http://www.scopus.com/inward/record.url?scp=0024338237&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024338237&partnerID=8YFLogxK

U2 - 10.1056/NEJM198908173210704

DO - 10.1056/NEJM198908173210704

M3 - Article

VL - 321

SP - 430

EP - 435

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 7

ER -